Novel Strategies for Spatiotemporal and Controlled BMP-2 Delivery in Bone Tissue Engineering

Novel Strategies for Spatiotemporal and Controlled BMP-2 Delivery in Bone Tissue Engineering

Blog Article

Bone morphogenetic protein-2 (BMP-2) has been commercially approved by the ivoryjinelle.com Food and Drug Administration for use in bone defects and diseases.BMP-2 promotes osteogenic differentiation of mesenchymal stem cells.In bone tissue engineering, BMP-2 incorporated into scaffolds can be used for stimulating bone regeneration in organoid construction, drug testing platforms, and bone transplants.

However, the high dosage and uncontrollable release rate of BMP-2 challenge its clinical application, mainly due to the short circulation half-life of BMP-2, microbial contamination in bone extracellular matrix hydrogel, and the delivery method.Moreover, in clinical translation, the requirement of high doses of BMP-2 for efficacy poses challenges in cost and safety.Based on these, novel strategies should ensure that BMP-2 is delivered precisely to the desired location within the body, regulating the timing of BMP-2 release to coincide with the bone lorenametaute.com healing process, as well as release BMP-2 in a controlled manner to optimize its therapeutic effect and minimize side effects.

This review highlights improvements in bone tissue engineering applying spatiotemporal and controlled BMP-2 delivery, including molecular engineering, biomaterial modification, and synergistic therapy, aiming to provide references for future research and clinical trials.